IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5

Early virological response End-of-treatment virological response Sustained virological response Age (continuous) 0.95 (0.82 to 1.09) 0.5 0.97 (0.88 to 1.07) 0.5 0.95 (0.89 to 1.01) 0.11 Male sex - - 4.38 (0.45 to 42.40) 0.2 1.50 (0.49 to 4.64) 0.5 BMI (continuous) 1.95 (0.96 to 3.95) 0.06 1.96 (1.10 to 3.49) 0.02 0.87 (0.69 to 1.11) 0.3 ALT (continuous) 0.99 (0.98 to 1.01) 0.3 0.99 (0.98 to 1.01) 0.3 0.99 (0.98 to 1.00) 0.13 Log HCV RNA (continuous) 0.71 (0.11 to 4.70) 0.7 0.78 (0.23 to 2.60) 0.7 0.49 (0.22 to 1.06) 0.07 rs8099917 (TT vs TG/GG) 0.67 (0.04 to 11.36) 0.8 0.41 (0.06 to 2.73) 0.4 1.04 (0.32 to 3.34) 0.9 rs1297960 (CC vs CT/TT) 1.19 (0.07 to 20.21) 0.9 0.77 (0.12 to 5.06) 0.8 1.20 (0.38 to 3.75) 0.8 Diabetes - - 0.24 (0.03 to 1.73) 0.2 1.05 (0.23 to 4.78) 0.9 Advanced fibrosis (F0-F2 vs F3-F4) - - - - 0.40 (0.08 to 2.06) 0.3 Use of pegylated IFN-α 8.40 (0.45 to 156.19) 0.15 6.67 (0.85 to 52.49) 0.1 0.43 (0.07 to 2.63) 0.4 Ribavirin dose reduction 0.24 (0.01 to 4.27) 0.3 1.06 (0.10 to 10.68) 1.0 0.67 (0.16 to 2.75) 0.6 ALT, alanine aminotransferase; BMI, body mass index; HCV, hepatitis C virus; IFN, interferon. [...]SNPs near IL28B do not appear to predict virological response to treatment in patients infected with HCV-5.